Why some patients with kidney diseases respond well to certain medications and others do not has continued to stump physicians. With no means to test the medications besides trial and error, finding the right treatment is often a frustrating experience for physicians and their patients.
Now, research at Johns Hopkins may help provide some answers to the puzzle.
By harvesting white blood cells from patients, placing the cells in tissue culture plates and exposing them to common steroid and immunosuppressant medications, scientists can predict in some cases what medications might work best for each patient.
If a patient's white blood cells are suppressed by the medications, it is hoped that the patient will respond favorably to treatment. By contrast, if the cells are insensitive to the medications, the test suggests that the traditional approach to treatment may be ineffective, and that either higher doses or more than one drug may be required.
An article on this research in the Journal of Clinical Pharmacology recently was selected by the American College of Clinical Pharmacology as the most promising article of the past year.
William A. Briggs, M.D., associate professor of nephrology, was principal investigator.
Briggs, of Timonium, Md., will be presented with the college's 1997 McKeen Cattell Memorial Award on September 18 in Phoenix at the association's 26th annual meeting. The award is named in memory of the late McKeen Cattell, first editor of the Journal of Clinical Pharmacology and co-founder of the college. It is presented annually to an author publishing an outstanding research paper in the journal.
"Individualizing treatment plans for patients is not a new idea in
medicine, but this is the first
time this notion has been applied to improve glomerular diseases," says Briggs.
"A major problem in
caring for these patients has been the lack of reliable clinical or laboratory
techniques for
'"/>
Contact: Karen Infeld
kinfeld@welchlink.welch.jhu.edu
(410)955-1534
Johns Hopkins Medical Institutions
16-Sep-1997